PPIDT00222
Drug Information
| Name | Catumaxomab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06607 |
| Type | biotech |
| Indication | For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label]. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution, concentrate | Intraperitoneal |
10 microgram
|
| Injection, solution, concentrate | Intraperitoneal |
50 microgram
|
| Injection, solution, concentrate | Intravenous |
|
| Solution | Intraperitoneal |
0.1 mg / mL
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P12318 | FCGR2A | Low affinity immunoglobulin gamma Fc region receptor II-a | Homo sapiens | agonist | Link |
| target | P08637 | FCGR3A | Low affinity immunoglobulin gamma Fc region receptor III-A | Homo sapiens | agonist | Link |
| target | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | Homo sapiens | agonist | Link |
| target | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | Homo sapiens | agonist | Link |
| target | P12314 | FCGR1A | High affinity immunoglobulin gamma Fc receptor I | Homo sapiens | agonist | Link |
| target | P16422 | EPCAM | Epithelial cell adhesion molecule | Homo sapiens | ligand | Link |